Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing clinical trials and pharmacological data without systematic review methodology
PubMed 29915923 · doi:10.1007/s40262-018-0668-z
What was done
This narrative review summarizes the pharmacokinetic profile, efficacy, and clinical utility of once-weekly subcutaneous semaglutide (0.5 mg or 1 mg) for type 2 diabetes mellitus, based on clinical trials comparing it as monotherapy or add-on therapy against placebo, sitagliptin, exenatide extended release, and insulin glargine.
What was found
Semaglutide exhibits a half-life of 7 days, reaching steady-state levels in 4 to 5 weeks. In clinical trials lasting 30 to 56 weeks, semaglutide produced a 1.5% to 1.9% reduction in HbA1c and a 5% to 10% reduction in body weight from baseline. It delays gastric emptying, potentially altering oral drug absorption, but requires no general dose adjustments and shows few drug interactions.
Why it matters
It outlines the clinical pharmacology and therapeutic role of semaglutide as an option for patients with type 2 diabetes who benefit from glycemic reduction and weight loss with minimal hypoglycemia risk.
Limits
The abstract describes a narrative overview rather than a systematic review or meta-analysis. Exact study sample sizes, specific adverse event rates, and measures of statistical precision are not reported.
Cited by
- supports Endogenous human GLP-1 has a half-life of only a few minutes, whereas semaglutide was molecularly modified to have a half-life of approximately 5 to 7 days.